BiotechTube

Olux-E Foam + Clobex lotion

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Plaque-Type Psoriasis

Conditions

Plaque-Type Psoriasis

Trial Timeline

Mar 1, 2009 → Aug 1, 2009

NCT ID
NCT00852761

About Olux-E Foam + Clobex lotion

Olux-E Foam + Clobex lotion is a approved stage product being developed by GSK plc for Plaque-Type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00852761. Target conditions include Plaque-Type Psoriasis.

What happened to similar drugs?

0 of 12 similar drugs in Plaque-Type Psoriasis were approved

Approved (0) Terminated (1) Active (11)
❌MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
🔄AIN457 150 mg + AIN457 300 mg + PlaceboNovartisPhase 3
🔄secukinumab 150 mgNovartisPhase 3
🔄Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: EtanerceptNovartisPhase 3
🔄Placebo + Secukinumab 150mg + Secukinumab 300mgNovartisPhase 3
🔄SecukinumabNovartisPhase 3
🔄Secukinumab (AIN457) + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00852761ApprovedCompleted

Competing Products

18 competing products in Plaque-Type Psoriasis

See all competitors
ProductCompanyStageHype Score
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32
AIN457 150 mg + AIN457 300 mg + PlaceboNovartisPhase 3
40
AIN457 + AIN457A + AIN457A + PlaceboNovartisPhase 2
35
secukinumab + placeboNovartisPhase 2
35
secukinumab 150 mgNovartisPhase 3
40
Experimental : Secukinumab low dose + Experimental: Secukinumab high dose + Placebo Comparator: Secukinumab Placebo + Active Comparator: EtanerceptNovartisPhase 3
40
Placebo + Secukinumab 150mg + Secukinumab 300mgNovartisPhase 3
40
SecukinumabNovartisPhase 3
40
AIN457 + PlaceboNovartisPhase 2
35
Secukinumab (AIN457) + PlaceboNovartisPhase 3
40
secukinumab 150 mg + placebo to secukinumab 150 mgNovartisPhase 3
40
secukinumab low dose + secukinumab high doseNovartisPhase 3
40
AIN457 150mg + AIN457 300mgNovartisPhase 3
40
secukinumab 150mg + secukinumab 10mg/kg i.v. regimenNovartisPhase 3
40
CJM112 + SecukinumabNovartisPhase 1
29
secukinumab 150 mg + secukinumab 300 mg + placeboNovartisPhase 3
40
AIN457 + PlaceboNovartisPhase 2
35
AN2728 Ointment + AN2728 VehiclePfizerPhase 1
29